Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions

Losy, Jacek; Niezgoda, Adam; Wender, M

doi:10.1016/s0165-5728(99)00092-2

Cited by 65 publications

(43 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The migration of inflammatory cells is facilitated by the upregulation of adhesion molecules, such as intercellular adhesion molecule 1, vascular-cell adhesion molecule 1, and platelet endothelial cell adhesion molecule 1 (10,11). On the other hand, matrix metalloproteinases (e.g., MMP-9) may degrade components of the basement membrane, and chemokines can form concentration gradients, which attract leukocytes, and activate leukocyte integrins, increasing adherence and extravasation (12,13).…”

mentioning

confidence: 99%

Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies

2007

Self Cite

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic demyelinating disease of the human central nervous system of a still unknown etiology. The autoimmune inflammatory process is believed to be essential for the development of the disease. Several different studies have shown that chemokines and chemokine receptors are involved in the pathogenesis of MS. Chemokines can mediate the trafficking of immune cells across the blood-brain barrier, and regulate their transfer to lesion sites. Chemokines were detected in actively demyelinating lesions and were found to be elevated in the cerebrospinal fluid of patients with MS during relapse. Different pairs of chemokine receptors and their ligands seem to play a pathogenic role in MS (e.g., CXCR3 and CXCL9, CXCL10; CCR1 and CCL3, CCL4, CCL5; CCR2 and CCL2; CCR5 and CCL3, CCL4, CCL5). Interfering with the chemokine system may be an effective therapeutic approach in MS. In this review we briefly summarize the results of the previous studies and identify the most important findings in the field.

show abstract

mentioning

confidence: 99%

Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies

2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…An increase of serum levels of sPECAM-1 is well documented in MS (Losy et al, 1999;Jimenez et al, 2005;Minagar et al, 2001;Kuenz et al, 2005. ), although studies have not been able to link genetic changes in PECAM-1 with MS (Sciacca et al, 2000;Nelissen et al 2000.…”

Section: Discussionmentioning

confidence: 92%

Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms

Reinke

Lee

Zozulya

et al. 2007

Journal of Neuroimmunology

View full text Add to dashboard Cite

The homotypic cell adhesion molecule PECAM-1 is a major participant in the migration of leukocytes across endothelium. We examined the ability of a chimeric soluble sPECAM-1 fused to human IgGFc to impair leukocyte entry through the blood-brain barrier and reduce CNS autoimmunity. sPECAM-Fc impaired migration of lymphocytes across brain endothelial monolayers and diminished the severity of EAE, an experimental model of MS, when administered at the onset of symptoms. However, in mice transgenic for sPECAM-Fc, the chronically elevated levels of sPECAM-Fc hastened onset of EAE disease without significantly changing clinical score severity. Our data suggests that short-term treatment of diseases like MS with sPECAM-Fc has therapeutic potential.

show abstract

“…Losy and Niezgoda [1] showed increased PECAM-1 in MS patients with gadolinium-enhancing lesions in comparison to patients with non-active lesions. They hypothesized direct involvement of PECAM-1 in the process of blood-brain barrier damage and secondary extravasation of leukocytes towards brain parenchyma.…”

Section: Central Nervous Systemmentioning

confidence: 93%

“…Because the native and soluble forms may have opposite effects [1,2]. Niezgoda and Losy hypothesized that the soluble forms are rather a sort of truncated false saturators for their natural counterpart which finally reduce the triggered inflammatory cascade [1,8]. They should be then considered a self-limiting negative feed-back mechanism of the CAM-activated inflammatory pathway (Fig.…”

Section: Cell Adhesion Molecule -Forms Timing Rolementioning

confidence: 99%

Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions

Cited by 65 publications

References 23 publications

Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies

Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies

Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms

Cell adhesion molecules and their possible role in the pathology of the peripheral nerves – a review of the literature

Contact Info

Product

Resources

About